Dipesh Uprety

1.7k total citations · 1 hit paper
71 papers, 1.0k citations indexed

About

Dipesh Uprety is a scholar working on Oncology, Pulmonary and Respiratory Medicine and Molecular Biology. According to data from OpenAlex, Dipesh Uprety has authored 71 papers receiving a total of 1.0k indexed citations (citations by other indexed papers that have themselves been cited), including 38 papers in Oncology, 33 papers in Pulmonary and Respiratory Medicine and 13 papers in Molecular Biology. Recurrent topics in Dipesh Uprety's work include Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (20 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Dipesh Uprety is often cited by papers focused on Lung Cancer Treatments and Mutations (29 papers), Lung Cancer Research Studies (20 papers) and Lung Cancer Diagnosis and Treatment (9 papers). Dipesh Uprety collaborates with scholars based in United States, Spain and France. Dipesh Uprety's co-authors include Alex A. Adjei, Sumithra J. Mandrekar, Dennis A. Wigle, Anja C. Roden, Howard West, Dongxiao Zhu, Janak Adhikari, Jordi Remón, Binay Kumar Shah and Stephanie P.L. Saw and has published in prestigious journals such as JAMA, Journal of Clinical Oncology and SHILAP Revista de lepidopterología.

In The Last Decade

Dipesh Uprety

64 papers receiving 994 citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial

2024 76 citations Egbert F. Smit, Enriqueta Felip et al. The Lancet Oncology profile →

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Dipesh Uprety United States	15	484	377	313	128	111	71	1.0k
Alessandro Inno Italy	20	695 1.4×	329 0.9×	258 0.8×	184 1.4×	92 0.8×	80	1.2k
Sung Hoon Sim South Korea	18	493 1.0×	325 0.9×	243 0.8×	230 1.8×	99 0.9×	81	1.0k
Prabhat Singh Malik India	17	493 1.0×	416 1.1×	379 1.2×	236 1.8×	50 0.5×	116	1.1k
Paolo Bironzo Italy	18	505 1.0×	637 1.7×	334 1.1×	191 1.5×	92 0.8×	100	1.2k
Anastasios Dimou United States	16	481 1.0×	311 0.8×	201 0.6×	115 0.9×	71 0.6×	67	800
Mehmet Alı Nahıt Şendur Türkiye	18	825 1.7×	446 1.2×	292 0.9×	158 1.2×	153 1.4×	183	1.4k
Gonçalo Forjaz United States	5	590 1.2×	639 1.7×	243 0.8×	237 1.9×	97 0.9×	11	1.1k
Rami Manochakian United States	17	686 1.4×	490 1.3×	330 1.1×	185 1.4×	64 0.6×	87	1.2k
Viljem Kovač Slovenia	20	292 0.6×	641 1.7×	247 0.8×	136 1.1×	122 1.1×	69	1.0k
Qiuhua Deng China	14	389 0.8×	552 1.5×	352 1.1×	259 2.0×	111 1.0×	38	1.1k

Countries citing papers authored by Dipesh Uprety

Since Specialization

Citations

This map shows the geographic impact of Dipesh Uprety's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Dipesh Uprety with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Dipesh Uprety more than expected).

Fields of papers citing papers by Dipesh Uprety

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Dipesh Uprety. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Dipesh Uprety. The network helps show where Dipesh Uprety may publish in the future.

Co-authorship network of co-authors of Dipesh Uprety

This figure shows the co-authorship network connecting the top 25 collaborators of Dipesh Uprety. A scholar is included among the top collaborators of Dipesh Uprety based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Dipesh Uprety. Dipesh Uprety is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Choucair, Khalil, Andrew Elliott, Matthew J. Oberley, et al.. (2025). Molecular and immune landscape of tumours in geriatric patients with non-small cell lung cancer, melanoma and renal cell carcinoma. PubMed. 4(1). e000551–e000551.

Sheffield, Kristin M., et al.. (2025). P1.17.49 Real-World Outcomes With IO and Chemo-IO Demonstrate Unmet Need for 1L KRAS G12C-Mutant Advanced NSCLC in the US. Journal of Thoracic Oncology. 20(10). S234–S234.

Uprety, Dipesh, et al.. (2025). Trends in the Incidence and Survival Outcomes in Patients With Small Cell Lung Cancer in the United States: An Analysis of the SEER Database. Cancer Medicine. 14(3). e70608–e70608. 5 indexed citations

Uprety, Dipesh, Devin Abrahami, Zachary A. Marcum, et al.. (2025). Brain metastases and mortality in patients with ALK + metastatic non-small cell lung cancer treated with second-generation ALK tyrosine kinase inhibitors as first-line targeted therapies: An observational cohort study. Lung Cancer. 201. 108436–108436.

Naidoo, Jarushka, Dipesh Uprety, Matthew P. Smeltzer, et al.. (2025). 50 Years of Progress in NSCLC: A New Fellow’s Guide in the Clinic. Journal of Thoracic Oncology. 20(10). 1392–1422.

Schram, Alison M., Gilberto Lopes, Elisa Fontana, et al.. (2024). 691TiP PYNNACLE phase II trial of rezatapopt (PC14586) in solid tumors with a TP53 Y220C mutation. Annals of Oncology. 35. S535–S536. 2 indexed citations

Smit, Egbert F., Enriqueta Felip, Dipesh Uprety, et al.. (2024). Trastuzumab deruxtecan in patients with metastatic non-small-cell lung cancer (DESTINY-Lung01): primary results of the HER2-overexpressing cohorts from a single-arm, phase 2 trial. The Lancet Oncology. 25(4). 439–454. 76 indexed citations breakdown →

Dudek, Arkadiusz Z., Joyce O’Shaughnessy, Sarina A. Piha‐Paul, et al.. (2024). A multicenter, open-label, phase 1a study of HC-5404 in patients with advanced solid tumors.. Journal of Clinical Oncology. 42(16_suppl). e15118–e15118. 10 indexed citations

Wang, Yating, et al.. (2024). Survival trends among patients with metastatic non–small cell lung cancer before and after the approval of immunotherapy in the United States: A Surveillance, Epidemiology, and End Results database–based study. Cancer. 131(1). e35476–e35476. 7 indexed citations

10.

Uprety, Dipesh, Jordi Remón, & Solange Peters. (2023). First-Line Dual Immunotherapy, a Treatment Option in First-Line Metastatic Non–Small-Cell Lung Cancer: Are We Ready to Use It?. Journal of Clinical Oncology. 42(4). 378–382. 5 indexed citations

11.

Richardson, Gary, Raed Moh’d Taiseer Al-Rajabi, Dipesh Uprety, et al.. (2023). A Multicenter, Open-Label, Phase I/II Study of FN-1501 in Patients with Advanced Solid Tumors. Cancers. 15(9). 2553–2553. 2 indexed citations

12.

Uprety, Dipesh & Howard West. (2023). Malignant Pericardial Effusion, or Fluid Around the Heart Due to Cancer. JAMA Oncology. 10(1). 148–148. 1 indexed citations

13.

Khan, Husain Yar, Misako Nagasaka, Yiwei Li, et al.. (2022). Inhibitor of the Nuclear Transport Protein XPO1 Enhances the Anticancer Efficacy of KRAS G12C Inhibitors in Preclinical Models of KRAS G12C–Mutant Cancers. Cancer Research Communications. 2(5). 342–352. 21 indexed citations

14.

Uprety, Dipesh, et al.. (2022). Challenges in the Use of Targeted Therapies in Non–Small Cell Lung Cancer. Cancer Research and Treatment. 54(2). 315–329. 39 indexed citations

15.

Nagasaka, Misako, Vijendra K. Singh, Yasmine Baca, et al.. (2021). The Effects of HER2 Alterations in EGFR Mutant Non-small Cell Lung Cancer. Clinical Lung Cancer. 23(1). 52–59. 21 indexed citations

16.

Uprety, Dipesh & Alex A. Adjei. (2020). KRAS: From undruggable to a druggable Cancer Target. Cancer Treatment Reviews. 89. 102070–102070. 186 indexed citations

17.

Uprety, Dipesh, et al.. (2018). Cytoreductive Nephrectomy in Elderly Patients with Metastatic Renal Cell Carcinoma in the Targeted Therapy Era. Anticancer Research. 38(5). 3013–3018. 2 indexed citations

18.

Uprety, Dipesh. (2018). Chemo-immunotherapy: The Beginning of a New Era in Lung Cancer. Clinical Lung Cancer. 20(2). 63–65. 3 indexed citations

19.

Uprety, Dipesh, et al.. (2016). Youtube as a source of information on cervical cancer. North American Journal of Medical Sciences. 8(4). 183–183. 39 indexed citations

20.

Uprety, Dipesh, et al.. (1973). Induction of salt tolerance in peas by Phosfon D and its mechanism of action. Science and Culture. 39(12). 544–547. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact